A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygoius for the ∆F508-CFTR Gene Mutation May 5, 2022 By Jesse Bufkin
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma May 5, 2022 By Jesse Bufkin
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer May 5, 2022 By Jesse Bufkin
Sleep & Obesity in Adolescents: A Nursing Exploration and Study of Feasibility May 5, 2022 By Jesse Bufkin
A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regi May 5, 2022 By Jesse Bufkin
Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/neu Negative Breast Cancer, A Phase II Study May 5, 2022 By Jesse Bufkin
A Mulit-center, Phase I, Open Label Dose-Escalation Vaccine Trial of Dher2 Protein with as15 Adjuvant in HER2-Overexpressing Patients with High Risk Breast Cancer-GSK#719125/002 May 5, 2022 By Jesse Bufkin
Misoprostol for In-Office Gynecological Procedures Involving Intrauterine Catheterization May 5, 2022 By Jesse Bufkin
